`
`From:
`Sent:
`To:
`CC:
`
`Subject:
`
`Re: WG: Lucentis feasibility study
`
`we lcome in the Lucentis team!
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION , SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH}01495912
`
`Novartis Exhibit 2143.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`30.03.2009 17:42
`
`Dear
`I would like to give you some more details and explanations regarding the Lucentis feasibility studies, which are "already"
`planned or to be planned .
`
`. .. but first of all I would like to introduce myself.
`did build up a complete project team during the last days/weeks to provide you the full develo~ ent service in
`-
`future. I'm the team member, which will be responsible for the process development (together with
`team), process implementation into the production and all the additional things around e.g. technical, p armaceutIcal or
`quality aspects.
`I'm working in the process development team sincellll thus some experiences especially with syringes are available.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH}01495912
`
`Novartis Exhibit 2143.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Please don't hesitate to contact me for further detailed questions; otherwise I'm looking forward to meet you on 8lh of April
`in -
`We are open for all discussions and are happy, if we could get as many information as possible about your product, to
`support you as much as possible.
`
`- -ds,
`
`27.03.2009 08:25
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH}01495912
`
`Novartis Exhibit 2143.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(CH)01495912
`
`Novartis Exhibit 2143.004
`Regeneron v. Novartis, IPR2021-00816
`
`